GILENYA Drug Patent Profile

Which patents cover Gilenya, and what generic alternatives are available?

Gilenya is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has ninety-eight patent family members in thirty-nine countries.

The generic ingredient in GILENYA is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gilenya

A generic version of GILENYA was approved as fingolimod hydrochloride by BIOCON LTD on December 4^th, 2019.

Summary for GILENYA

International Patents:	98
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	33
Patent Applications:	987
Drug Prices:	Drug price information for GILENYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GILENYA
What excipients (inactive ingredients) are in GILENYA?	GILENYA excipients list
DailyMed Link:	GILENYA at DailyMed

See drug prices for GILENYA

Recent Clinical Trials for GILENYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of South Carolina	PHASE2
The Methodist Hospital Research Institute	Phase 2
Hikma Pharmaceuticals LLC	Phase 1

See all GILENYA clinical trials

Pharmacology for GILENYA

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Paragraph IV (Patent) Challenges for GILENYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for GILENYA

GILENYA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018		RX	Yes	No					Y
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes

Expired US Patents for GILENYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010

International Patents for GILENYA

When does loss-of-exclusivity occur for GILENYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GILENYA around the world.

Country	Patent Number	Title	Estimated Expiration
Tunisia	2013000396	FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL] PROPANE -1, 3 - DIOL
Poland	3143990
World Intellectual Property Organization (WIPO)	2011041146

Supplementary Protection Certificates for GILENYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613288	2011/027	Ireland		PRODUCT NAME: GILENYA-FINGOLIMOD; NAT REGISTRATION NO/DATE: EU/1/11/677/001 20110317; FIRST REGISTRATION NO/DATE: EU/1/11/677/002 17/03/2011 IRELAND EU/1/11/677/003 17/03/2011 IRELAND EU/1/11/677/004 20110317
1613288	SPC/GB11/045	United Kingdom		PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
0627406	C00627406/01	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH

Gilenya (Fingolimod) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial performance of Gilenya (fingolimod), a sphingosine-1-phosphate (S1P) receptor modulator used for the treatment of relapsing forms of multiple sclerosis (MS). The analysis covers patent landscape, market share, sales performance, and projected future trajectory, providing insights for strategic R&D and investment decisions.

What is Gilenya's Patent Status and Exclusivity?

Gilenya's primary composition of matter patent (U.S. Patent No. 6,001,280) expired in the United States in late 2019. This expiration marked a critical juncture for the drug's market exclusivity, paving the way for generic competition. Novartis, the originator, held the patent on the active pharmaceutical ingredient, fingolimod hydrochloride.

• Key Patent Expiration: U.S. Patent No. 6,001,280 (Composition of Matter) – Expired November 2019.
• European Patent: EP 0894076 B1 (Composition of Matter) – Expired in various European countries throughout 2019 and 2020.
• Secondary Patents: While the core composition of matter patents have expired, Novartis had pursued secondary patents covering methods of use, formulations, and manufacturing processes. These secondary patents could provide some residual protection, but their impact on broad market exclusivity is generally less significant than composition of matter patents.
• Pediatric Exclusivity: In the U.S., Gilenya received six months of pediatric exclusivity in 2008, extending its market exclusivity until March 2010. This was a standard regulatory incentive for conducting pediatric studies.
• Orphan Drug Exclusivity: In the U.S. and EU, fingolimod was granted orphan drug exclusivity for certain indications, providing a period of market protection. However, this exclusivity has largely expired for the primary MS indication.

The expiration of primary patents has led to the introduction of generic versions of fingolimod, significantly impacting Gilenya's market share and revenue.

How Has Gilenya Performed Financially?

Gilenya was a significant revenue driver for Novartis. Its sales trajectory reflects the typical lifecycle of a successful pharmaceutical product, characterized by rapid growth in its initial years, sustained peak sales, and subsequent decline following patent expiration and generic entry.

Year	Net Sales (Billions USD)
2011	$0.47
2012	$1.06
2013	$1.60
2014	$1.96
2015	$2.29
2016	$2.37
2017	$2.41
2018	$2.39
2019	$2.25
2020	$1.94
2021	$1.46
2022	$0.99
2023	$0.57

(Source: Novartis Annual Reports, Financial Filings)

Key Observations:

• Peak Sales: Gilenya reached its peak annual sales in 2017 and 2018, exceeding $2.3 billion.
• Post-Patent Expiration Decline: Following the expiration of key patents in the U.S. (2019) and subsequent generic launches, Gilenya's sales experienced a sharp and consistent decline.
• Generic Erosion: By 2023, net sales had fallen to $0.57 billion, demonstrating the substantial impact of generic competition. The introduction of multiple generic versions has fragmented the market and driven down prices.

What is the Current Market Landscape for Fingolimod?

The market for fingolimod is now characterized by robust generic competition. Following patent expirations, several pharmaceutical companies have launched generic fingolimod products, primarily in the United States and Europe. This has fundamentally altered the competitive dynamics, shifting from a single-brand market to a multi-generic one.

• Key Generic Players: While specific market share data for individual generic manufacturers fluctuates, companies like Viatris, Teva Pharmaceuticals, Mylan (now part of Viatris), and Sun Pharmaceutical have been active in launching generic fingolimod.
• Pricing Pressure: The presence of multiple generic competitors has exerted significant downward pressure on prices. This is a standard outcome in the pharmaceutical market after patent expiries.
• Market Share Shift: Gilenya's market share, once dominant for oral S1P modulators, has been progressively eroded by these generic alternatives. Payers and healthcare providers often favor lower-cost generic options when efficacy and safety profiles are comparable.
• Geographic Variations: The pace of generic entry and subsequent market share shifts can vary by region due to different patent laws, regulatory approval timelines, and market access dynamics in each country.

The current market landscape is highly competitive, with pricing and market access strategies being critical for both branded and generic players.

What are the Clinical and Regulatory Considerations for Fingolimod?

Fingolimod's clinical profile and regulatory history have shaped its market adoption and continue to influence its use post-patent expiry.

• Mechanism of Action: Fingolimod is a first-in-class S1P receptor modulator. It works by trapping lymphocytes in lymph nodes, reducing their migration into the central nervous system (CNS) and thereby decreasing inflammation associated with MS.
• Indication: Approved for the treatment of relapsing forms of multiple sclerosis (RRMS) in adults. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
• Key Safety Concerns: Fingolimod carries significant safety warnings and precautions, including:
  • Bradycardia: Initial dose dip in heart rate can be serious.
  • Macular Edema: Swelling in the retina.
  • Infections: Increased risk of opportunistic infections, including progressive multifocal leukoencephalopathy (PML).
  • Liver Enzyme Elevations: Potential for liver injury.
  • Respiratory Effects: Decreased forced expiratory volume in one second (FEV1).
  • Fetal Harm: Contraindicated in pregnancy.
• Regulatory Approvals:
  • U.S. FDA: Approved September 2010.
  • European Medicines Agency (EMA): Approved October 2011.
• Post-Marketing Surveillance: Ongoing monitoring of safety data has been crucial. This includes pharmacovigilance efforts to identify rare but serious adverse events.
• Evolving Treatment Landscape: The S1P modulator class has expanded significantly with the introduction of newer agents like siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvrio). These newer agents often have different pharmacokinetic profiles, potentially improved safety profiles, and are approved for specific sub-types of MS or have distinct dosing regimens. This competition further challenges fingolimod's market position.

The established safety profile and the availability of newer, potentially safer or more targeted S1P modulators are key considerations for prescribers and patients when choosing treatment.

What is the Future Market Outlook for Fingolimod?

The future market outlook for fingolimod is one of continued decline in terms of revenue and market share for the branded product. However, the generic market for fingolimod is expected to remain active.

• Branded Gilenya: Novartis has strategically shifted focus to newer, higher-margin therapies within its neuroscience portfolio, including Kesimpta (ofatumumab) and potentially other S1P modulators in development or recently launched. Gilenya's contribution to Novartis's overall revenue will continue to diminish.
• Generic Fingolimod: The generic fingolimod market will persist as a significant segment for manufacturers able to produce the drug cost-effectively. Pricing competition will remain intense. The market share within the generic segment will depend on manufacturing efficiency, supply chain reliability, and marketing efforts by generic companies.
• Competition from Newer S1P Modulators: The success of newer oral and injectable S1P modulators with potentially improved efficacy and safety profiles (e.g., ozanimod, ponesimod, siponimod, and ofatumumab) will continue to capture market share from both branded Gilenya and generic fingolimod. These newer agents offer differentiated clinical benefits and target specific patient populations or disease severities.
• Market Penetration: The overall market for MS treatments is growing, driven by increased diagnosis rates and greater awareness of treatment options. However, fingolimod's share of this growing market is expected to shrink.
• Geographic Diversification: Generic fingolimod's penetration will continue to expand in emerging markets as healthcare systems adopt cost-effective generic options.
• Potential for Formulation/Delivery Innovation: While less likely for a product with significant generic competition, some companies might explore niche formulations or delivery methods for fingolimod if a clear unmet need or patentable innovation emerges, though this is a low probability scenario given the competitive landscape.

The trajectory for fingolimod is firmly established as one of declining branded sales and a stable but competitive generic market, facing ongoing pressure from newer therapeutic agents.

What are the Key Competitive Factors in the Fingolimod Market?

The competitive landscape for fingolimod is shaped by several critical factors, impacting both the branded product and its generic alternatives.

• Price: For generic fingolimod, price is the paramount competitive factor. Manufacturers with lower production costs can offer more aggressive pricing, thereby gaining market share from competitors and the branded product. For branded Gilenya, pricing strategies become more challenging post-patent expiry.
• Market Access and Payer Coverage: Securing favorable formulary placement and reimbursement from payers (insurance companies, government health programs) is crucial. Generic manufacturers often achieve wider market access due to lower costs. Novartis's ability to negotiate access for Gilenya against generics and newer therapies has become more complex.
• Clinical Efficacy and Safety Profiles: While fingolimod has a well-established efficacy profile, newer S1P modulators offer potential advantages in terms of safety, tolerability, and specific indications. Prescribers and patients evaluate these factors when making treatment decisions. The known safety risks of fingolimod (bradycardia, macular edema, infections) are a significant consideration.
• Physician Prescribing Habits: Physician familiarity and confidence with a particular drug, established prescribing patterns, and perceived advantages of newer agents influence prescription volumes. Key Opinion Leaders (KOLs) in neurology play a role in shaping these habits.
• Generic Availability and Supply Chain Reliability: The consistent availability of generic fingolimod from multiple suppliers is essential. Supply chain disruptions or stock-outs can lead to patients switching to alternatives.
• Marketing and Sales Efforts: Even for generics, targeted marketing to physicians and pharmacies is necessary. For branded Gilenya, significant marketing efforts are required to defend its position against generics and newer entrants, focusing on its long-term clinical experience.
• Patient Support Programs: Programs that assist patients with access, adherence, and managing side effects can influence brand loyalty and market share for branded products. These are less common for generic products.
• Competition within the S1P Modulator Class: The success of newer oral S1P modulators like ozanimod, siponimod, and ponesimod, as well as injectable options like ofatumumab, directly competes for patients who might otherwise be prescribed fingolimod. These newer agents often claim differentiated benefits in terms of safety or targeted efficacy.

These factors collectively determine the market share and financial success of fingolimod-based therapies.

Key Takeaways

• Gilenya's primary composition of matter patent expired in late 2019 in the U.S., initiating a period of significant generic competition.
• Sales for branded Gilenya have declined sharply from peak annual revenues exceeding $2.3 billion to $0.57 billion in 2023 due to generic erosion.
• The market for fingolimod is now highly competitive with numerous generic manufacturers offering lower-priced alternatives.
• Fingolimod's established efficacy is balanced by significant safety concerns, including bradycardia, macular edema, and increased infection risk, which are critical considerations for prescribers.
• The emergence of newer S1P receptor modulators with potentially improved safety and efficacy profiles is a major competitive threat to both branded Gilenya and generic fingolimod.
• The future outlook for branded Gilenya is one of continued revenue decline, while the generic fingolimod market is expected to persist, driven by cost-effective production and market access.

Frequently Asked Questions

1. When did the main patent for Gilenya expire in the U.S.? The primary composition of matter patent for Gilenya (fingolimod) expired in November 2019 in the United States.

2. What is the main mechanism of action for Gilenya? Gilenya is a sphingosine-1-phosphate (S1P) receptor modulator that works by trapping lymphocytes in lymph nodes, thereby reducing their migration into the central nervous system and decreasing inflammation associated with multiple sclerosis.

3. What are the most significant safety concerns associated with Gilenya? Key safety concerns include bradycardia (slow heart rate), macular edema (retinal swelling), increased risk of infections (including PML), liver enzyme elevations, and potential respiratory effects.

4. Are there newer S1P receptor modulators that compete with Gilenya? Yes, newer S1P modulators such as siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvrio), and ofatumumab (Kesimpta) are active competitors in the multiple sclerosis market.

5. What is the projected financial future for branded Gilenya? The financial future for branded Gilenya is projected to be one of continued revenue decline as generic competition and newer therapies capture market share.

Citations

[1] Novartis AG. (2012-2023). Annual Reports and Financial Statements. Basel, Switzerland.

[2] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA website - specific patent information often found via Orange Book or drug database searches]

[3] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA website - specific drug information can be searched]